Therefore, investigating the mechanisms, risk factors, prognostic implications, and optimal strategies for managing adverse effects arising from the concurrent T-DM1 with radiotherapy in HER-2-positive breast cancer will enable clinicians to better understand these interactions, implement interventions timely, and improve patient’s survival and quality of life ultimately. This evidence concerns the gene ERBB2 and breast carcinoma.